| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Fmoc-Lys(N3)-OH targets peptide synthesis and bioconjugation applications. The azide side chain serves as a handle for click chemistry, allowing the introduction of various functionalities into peptides and proteins. It is used to create bioconjugates and study protein interactions. The compound enables site-specific modification of peptides. Its mechanism of action is related to its role in CuAAC reactions with alkyne-containing molecules.
|
|---|---|
| ln Vitro |
In vitro activity of Fmoc-Lys(N3)-OH is primarily as a click chemistry reagent. The azide group can undergo CuAAC with alkyne-containing molecules to form stable triazole linkages. This enables the modification of peptides and proteins with various labels, probes, or functional groups. The compound is used in peptide synthesis to introduce azide groups for further modifications. It is not directly biologically active in cell-based assays.
|
| ln Vivo |
There is no specific in vivo activity data for Fmoc-Lys(N3)-OH as a standalone compound. Peptides containing azide-functionalized lysine residues synthesized using this building block can be used for in vivo bioconjugation studies via click chemistry. The azide handle allows for the attachment of imaging agents, drugs, or other functional moieties to peptides for in vivo applications. Animal studies would be performed on the final conjugated products.
|
| Enzyme Assay |
In vitro enzyme/receptor binding protocols for Fmoc-Lys(N3)-OH involve its use as a click chemistry reagent. The compound is incorporated into peptides via SPPS. Standard Fmoc chemistry: the compound is activated with coupling reagents and coupled to resin-bound peptides. The azide group is stable under standard peptide synthesis conditions. After peptide synthesis and deprotection, the azide-containing peptide can be reacted with alkyne-containing molecules in CuAAC reactions. Purity is ≥95-99.7% by HPLC.
|
| Cell Assay |
Cell-based protocols for Fmoc-Lys(N3)-OH involve its use in labeling studies. Cells can be treated with azide-containing peptides or proteins synthesized using this building block. The azide group enables CuAAC with alkyne-labeled probes. Alternatively, azide-containing peptides can be tested in cell culture for various biological activities. Peptides are dissolved in DMSO or appropriate buffers and added to cells at 0.1-100 µM. The azide functionality allows for subsequent labeling and detection.
|
| Animal Protocol |
Animal studies with Fmoc-Lys(N3)-OH are not conducted directly. Peptides containing azide-functionalized lysine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes. The azide handle enables site-specific conjugation of imaging agents or drugs for in vivo applications. Biodistribution and efficacy studies can be performed depending on the conjugated moiety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Lys(N3)-OH is not applicable as it is a research building block. The compound has molecular weight 394.43 g/mol and formula C₂₁H₂₂N₄O₄. Melting point is 94-97°C and optical rotation is -12.8 ± 2° (c=1 in DMF). Store as powder at -20°C. The Fmoc group is removed under basic conditions during peptide synthesis. The azide handle is stable and available for click chemistry conjugation.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-Lys(N3)-OH is limited. The compound is for research use only. The azide group can be potentially hazardous; handle with care. Standard safety precautions should be observed. Store as powder at -20°C. Proper personal protective equipment should be worn. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| Additional Infomation |
Fmoc-Lys(N3)-OH (CAS#: 159610-89-6) is also known as Nα-Fmoc-Nε-azide-L-lysine, Fmoc-ε-azido-Nle-OH, and (2S)-N-Fmoc-6-Azido-Hexanoic Acid. Its molecular formula is C₂₁H₂₂N₄O₄ and molecular weight is 394.43. Purity is ≥95-99.7%. It is a click chemistry reagent with an azide group used in peptide synthesis and protein modification. It has no approved therapeutic indications.
|
| Molecular Formula |
C21H22N4O4
|
|---|---|
| Molecular Weight |
394.42379
|
| Exact Mass |
394.164
|
| CAS # |
159610-89-6
|
| PubChem CID |
25146063
|
| Appearance |
White to off-white powder
|
| Melting Point |
78 °C(dec.)
|
| LogP |
4.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
29
|
| Complexity |
600
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[N-]=[N+]=NCCCC[C@@H](C(O)=O)NC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O
|
| InChi Key |
PJRFTUILPGJJIO-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C21H22N4O4/c22-25-23-12-6-5-11-19(20(26)27)24-21(28)29-13-18-16-9-3-1-7-14(16)15-8-2-4-10-17(15)18/h1-4,7-10,18-19H,5-6,11-13H2,(H,24,28)(H,26,27)/t19-/m0/s1
|
| Chemical Name |
(2S)-6-azido-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
|
| Synonyms |
Fmoc-Lys（N3）-OH; N6-Diazo-L-Fmoc-lysine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~253.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5354 mL | 12.6768 mL | 25.3537 mL | |
| 5 mM | 0.5071 mL | 2.5354 mL | 5.0707 mL | |
| 10 mM | 0.2535 mL | 1.2677 mL | 2.5354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
